With the first doses of Moderna’s vaccine rolling out to frontline workers across the country, it’s easy to forget that the company behind this crucial tool toward ending the pandemic is itself little more than a startup.
Subscribe to the Crunchbase Daily
To deliver a vaccine for mass inoculation with 94.5 percent efficacy in clinical trials in under 11 months is obviously in itself an astonishing achievement.
But what makes Moderna‘s accomplishment all the more remarkable is that the company behind the effort got its start less than a decade ago and went public only two years ago. Its …
Related posts:
The Week’s 10 Biggest Funding Rounds: Amazon Aggregator Thrasio, Productivity Software And Healthtec...
The Briefing: Udemy Slips In First Day On Nasdaq, Kurly Eyes Market Debut, And More
VC Dealmaking Has Reached a Crescendo, But This Isn’t 1999 All Over Again
The Briefing: CRED Picks Up $251M, Delivery Hero Backs Gorillas, And More
